ProBioGen Signs Deal with Leading Biopharmaceutical Company for Cell Line Development

Berlin (ots) - ProBioGen AG, Berlin, Germany announces that it has entered into a cell line development programme with Millennium Pharmaceuticals, Inc., of Cambridge, Mass., USA. Under the customised programme, ProBioGen will use its Position Mediated Expression Enhancement (PMEE) strategy, which has been proved highly successful in the development of high yielding cell lines, to develop cell lines for the Company's antibodies and manufacture pre-clinical trial materials.

Through the use of Boost Elements and a specific design, ProBioGen is in the position to shorten development time and meet customer expectations even under aggressive timelines.

"This collaboration with one of the most successful US biopharmaceutical companies is an important step in our internationalisation strategy." said Michael Schlenk, Chief Executive Officer of ProBioGen.

About ProBioGen

ProBioGen offers services in the research and production for pharmaceutical and biotechnology companies at its certified cGMP (Good Manufacturing Practice), multi-purpose production facilities. The range of products and services includes the development of highly productive cell-lines, the production of glycoproteins for R&D and clinical testing, as well as the production of viral vectors and antibodies for in vitro diagnostics. The company is specialised in mammalian cells and combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen thus accompanies its clients from the early development of lead candidates up to late phase clinical development.

ProBioGen is a German biotechnology company founded 1994 as a spin-off from the university hospital Charité in Berlin.


Michael Schlenk

Goethestraße 54

D-13086 Berlin

+49 (0) 30 - 924 006-16